Results 51 to 60 of about 852 (150)

Angiopoietin-Like 3 (ANGPTL3) and Atherosclerosis: Lipid and Non-Lipid Related Effects

Journal of Cardiovascular Development and Disease, 2018
Genetic and clinical studies have demonstrated that loss-of-function variants in the angiopoietin-like 3 (ANGPTL3) gene are associated with decreased plasma levels of triglycerides (TGs), low-density lipoprotein cholesterol (LDL-C), and high-density ...
Maria Giovanna Lupo, Nicola Ferri
doaj   +1 more source

Proteome‐Wide Mendelian Randomization Identifies Candidate Causal Proteins for Cardiovascular Diseases

Advanced Genetics, Volume 6, Issue 2, June 2025.
Here, causal relations are examined between 2940 plasma proteins and 19 cardiovascular diseases (CVD) using a human genetics‐based method. 218 proteins are found whose blood levels influence CVD risks, with about half being new discoveries and largely confirmed in an independent cohort.
Chen Li, Nicolas De Jay, Shan‐Shan Zhang, Xin Fang, Supriya Sharma, Katrina A. Catalano, Venkatesh Sridharan, Zhaoqing Wang, Lei Zhao, Joseph D. Szustakowski, Ching‐Pin Chang, Joseph C. Maranville, Emily R. Holzinger, Erika M. Kvikstad   +13 more
wiley   +1 more source

A mini-review of efficacy, safety, and influence of novel evinacumab on familial hypercholesterolemia

The Egyptian Journal of Internal Medicine
Background Familial hypercholesterolemia (FH) poses a substantial risk of cardiovascular diseases. The recent approval of evinacumab signifies a breakthrough in FH management.
Gbolahan Olatunji, Emmanuel Kokori, Abdulrahmon Akanmu Moradeyo, Kaleb Lema, Olanipekun Ridwan Ayo, Opabode Muntaqim Obasanjo, Mubarak Jolayemi Mustapha, Anthony Chidera Stanley, Nicholas Aderinto   +8 more
doaj   +1 more source

Evinacumab for the treatment of homozygous familial hypercholesterolaemia: first patient case report in Switzerland

Swiss Medical Weekly
We present the first case in Switzerland of a patient with homozygous familial hypercholesterolaemia treated with evinacumab, a new recombinant human monoclonal antibody currently approved in Europe and in the USA but not yet in Switzerland.
Noé Corpataux, Fabienne Aregger, Konstantinos C. Koskinas, Catherine Gebhard   +3 more
doaj   +1 more source

Depletion of Hepatic SREBP2 Protects Against Hypercholesterolemia and Atherosclerosis through the ANGPTL3‐LPL Axis

Advanced Science, Volume 12, Issue 18, May 15, 2025.
This study reveals a novel crosstalk between hepatic SREBP2‐mediated cholesterol biosynthesis pathway and peripheral lipoprotein lipase‐mediated lipolysis pathway in the regulation of systemic lipid metabolism. Notably, the lipid‐lowering effects of SREBP2 inhibition are independent of a functional LDL receptor, highlighting the potential of acute ...
Yifan Wang, Jia You Sarafina Choe, Yu Shi, Thi Tun Thi, Xiaoyun Cao, Yang Hu, Kai Yan Cheng, Hui Li, Yang Ji, Yan Liu, Matthew Ackers‐Johnson, Roger S.Y. Foo, Yujia Shen, Haojie Yu   +13 more
wiley   +1 more source

Antibodies to watch in 2020

mAbs, 2020
This 2020 installment of the annual ‘Antibodies to Watch’ series documents the antibody therapeutics approved in 2019 and in regulatory review in the United States or European Union, as well as those in late-stage clinical studies, as of November 2019 ...
Hélène Kaplon, Mrinalini Muralidharan, Zita Schneider, Janice M. Reichert   +3 more
doaj   +1 more source

Emergency Management of Intoxication‐Type Inherited Metabolic Disorders

Journal of Inherited Metabolic Disease, Volume 48, Issue 2, March 2025.
ABSTRACT In many intoxication‐type inherited metabolic disorders, the accumulation of the toxic chemical can cause acute life‐threatening emergencies. Sometimes this is the inevitable consequence of a severe metabolic defect, but it is often triggered by catabolism.
J. Dexter Tarr, Andrew A. M. Morris
wiley   +1 more source

Evinacumab and Cardiovascular Outcome in Patients With Homozygous Familial Hypercholesterolemia

Arteriosclerosis, Thrombosis, and Vascular Biology
BACKGROUND: Patients with homozygous familial hypercholesterolemia (HoFH) remain at very high cardiovascular risk despite the best standard of care lipid-lowering treatment. The addition of evinacumab, an angiopoietin-like protein 3 monoclonal antibody, more than halves low-density lipoprotein cholesterol in short-term studies.
Béliard, Sophie, Saheb, Samir, Litzler-Renault, Stéphanie, Vimont, Alexandre, Valero, René, Bruckert, Éric, Farnier, Michel, Gallo, Antonio   +7 more
openaire   +4 more sources

Hypercholesterolemia and inflammation—Cooperative cardiovascular risk factors

European Journal of Clinical Investigation, Volume 55, Issue 1, January 2025.
Abstract Background Maintaining low concentrations of plasma low‐density lipoprotein cholesterol (LDLc) over time decreases the number of LDL particles trapped within the artery wall, slows the progression of atherosclerosis and delays the age at which mature atherosclerotic plaques develop.
Antonio Gallo, Wilfried Le Goff, Raul D. Santos, Isabella Fichtner, Stefano Carugo, Alberto Corsini, Cesare Sirtori, Massimiliano Ruscica   +7 more
wiley   +1 more source

Perioperative management in pediatric domino liver transplantation for metabolic disorders: A narrative review

Pediatric Anesthesia, Volume 34, Issue 11, Page 1107-1118, November 2024.
Abstract Domino liver transplantation and domino‐auxiliary partial orthotopic liver transplantation are emerging techniques that can expand the liver donor pool and provide hope for children with liver disease. The innovative technique of domino liver transplantation has emerged as a pioneering strategy, capitalizing on structurally preserved livers ...
Ahmed Uslu, Nedim Çekmen, Adnan Torgay, Mehmet Haberal   +3 more
wiley   +1 more source